Effects of dietary sodium butyrate on hepatic biotransformation and pharmacokinetics of erythromycin in chickens

Investigations on hepatic and intestinal drug-metabolizing cytochrome P450 enzymes in wild boar compared to domestic swine

Drug-metabolizing cytochrome P450 (CYP) enzymes are especially important in wild animals as they are directly exposed to environmental pollutants and bioactive molecules of plants. Our main goal was to monitor the activity of certain CYP enzymes in wild boar compared to domestic swine, and to assess various modulatory factors of xenobiotic biotransformation in wild boar. Liver and intestinal mucosa (duodenum, jejunum, ileum, caecum) samples were collected from 49 hunted free-range wild boars and 15 wild boar fetuses; domestic pig samples (n = 40) were gained from a slaughter house. Specific activity of CYP1A2, CYP2C9, and CYP3A4 enzymes was assessed by luminometric assays. The activity of hepatic CYP1A2 and CYP3A4 enzymes was significantly higher in wild boars than in domestic pigs, while CYP2C9-mediated hepatic metabolism was significantly less intense in wild boars than in pigs. Certain modulatory factors (sex, sexual maturation, and season) were also confirmed in wild boars. The activity of all investigated intestinal CYP enzymes remained under detection level in each gut section in both species. Hepatic CYP2C9 and CYP3A4 enzymes were measurable in wild boar fetuses, but their activity was remarkably lower than in adults. The described interspecies differences might be explained with the altered exposure of wild and domesticated animals to specific CYP modulators. As CYP enzymes in wild boars can be highly influenced by environmental pollutants, following further studies, they may serve as ecotoxicological markers of agricultural or industrial toxicants. Investigating CYP-related drug metabolism in wildlife species can clarify some toxicokinetic interactions, thus having huge importance in the production of safe game meat.

Alteration of avian hepatic cytochrome P450 gene expression and activity by certain feed additives

We investigated the effect of four feed additives, namely β-glucan, a drinking water acidifier (DWA), a sanguinarine-containing product (SN) and fulvic acid, on hepatic cytochrome P450 (CYP) mRNA expression and CYP enzyme activity in chickens. The test substances were given to the chickens in the recommended dose or in tenfold dose. The administration of 5 mg/kg body weight (bw) β-glucan and 0.1 ml/kg bw DWA for five days decreased the relative gene expression of CYP1A4 and CYP2C23a. The dosing of 50 mg/kg bw β-glucan, 5 and 50 mg/kg bw SN, 1 ml/kg bw DWA and 250 mg/kg bw fulvic acid doubled the hepatic CYP1A4 activity. The activity of CYP2C and CYP3A remained unchanged. Avoidance of CYP1A-mediated feed-drug interactions requires accurate dosing of β-glucan, DWA and fulvic acid. According to our results, no treatment resulted in excessive or less CYP2C and CYP3A protein formation, which reduces the risk of potential feed additive-drug interactions in chickens. However, the administration of feed additive SN containing a plant alkaloid should be avoided concomitantly with CYP1A-metabolised medicines.

Feed-drug interaction of orally applied butyrate and phenobarbital on hepatic cytochrome P450 activity in chickens

The expression of hepatic drug-metabolizing cytochrome P450 (CYP) enzymes may be affected by several nutrition-derived compounds, such as by the commonly applied feed additive butyrate, possibly leading to feed-drug interactions. The aim of this study was to provide some evidence if butyrate can alter the activity of hepatic CYPs in chickens exposed to CYP-inducing xenobiotics, monitoring for the first time the possibility of such interaction. Ross 308 chickens in the grower phase were treated with daily intracoelomal phenobarbital (PB) injection (80 mg/kg BW), applied as a non-specific CYP-inducer, simultaneously with two different doses of intra-ingluvial sodium butyrate boluses (0.25 and 1.25 g/kg BW) for 5 days. Activity of CYP2H and CYP3A subfamilies was assessed by specific enzyme assays from isolated liver microsomes. According to our results, the lower dose of orally administered butyrate significantly attenuated the PB-triggered elevation of both hepatic CYP2H and CYP3A activities, which might be in association with the partly common signalling pathways of butyrate and CYP-inducing drugs, such as that of PB. Based on these data, butyrate may take part in pharmacoepigenetic interactions with simultaneously applied drugs or other CYP-inducing xenobiotics, with possible consequences for food safety and pharmacotherapy. Butyrate was found to be capable to maintain physiological CYP activity by attenuating CYP induction, underlining the safety of butyrate application in poultry nutrition.